Repligen Financials

RGEN Stock  USD 163.63  0.29  0.18%   
Based on the analysis of Repligen's profitability, liquidity, and operating efficiency, Repligen is not in a good financial situation at this time. It has a very high probability of going through financial hardship in March. At this time, Repligen's Retained Earnings are very stable compared to the past year. As of the 29th of January 2026, Cash is likely to grow to about 914.5 M, while Net Debt is likely to drop (67.2 M).
 
Oil Shock
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes

Repligen Balance Sheet Chart

At this time, Repligen's Retained Earnings are very stable compared to the past year. As of the 29th of January 2026, Cash is likely to grow to about 914.5 M, while Net Debt is likely to drop (67.2 M).
Key indicators impacting Repligen's financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Debt Equity Ratio0.330.31
Notably Up
Slightly volatile
Current Ratio9.479.67
Fairly Down
Very volatile
The essential information of the day-to-day investment outlook for Repligen includes many different criteria found on its balance sheet. An individual investor should monitor Repligen's cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Repligen.

Net Income

(24.11 Million)

  
Build AI portfolio with Repligen Stock

Repligen Earnings Geography

Repligen Stock Summary

Repligen competes with Avantor, Masimo, Baxter International, AptarGroup, and Bio Rad. Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts. Repligen operates under Medical Instruments Supplies classification in the United States and is traded on NASDAQ Exchange. It employs 1852 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
ISINUS7599161095
Business AddressBuilding 1, Waltham,
SectorLife Sciences Tools & Services
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitewww.repligen.com
Phone781 250 0111
CurrencyUSD - US Dollar

Repligen Key Financial Ratios

Repligen Key Balance Sheet Accounts

202120222023202420252026 (projected)
Total Assets2.4B2.5B2.8B2.8B3.3B3.4B
Other Current Liab55.8M63.3M46.4M66.3M76.3M80.1M
Net Debt(237.8M)(100.5M)(39.5M)(71.1M)(64.0M)(67.2M)
Retained Earnings194.1M397.3M438.8M407.4M468.5M491.9M
Cash603.8M523.5M751.3M757.4M871.0M914.5M
Net Receivables117.4M116.2M124.2M134.1M154.2M161.9M
Inventory184.5M238.3M202.3M143.0M164.4M172.6M
Other Current Assets25.9M19.8M33.2M31.6M36.3M38.2M
Total Liab608.3M620.9M853.2M856.9M985.5M1.0B
Total Current Assets931.7M998.1M1.1B1.1B1.2B1.3B
Accounts Payable36.2M27.6M19.6M32.1M37.0M38.8M
Short Term Debt263.6M291.6M75.1M15.1M17.4M16.5M
Intangible Assets337.3M360.6M400.5M397.9M457.6M480.5M
Other Assets28.2M2.5M1.7M282.1M253.9M266.6M
Common Stock553K556K558K561K645.2K408.0K
Other Liab32.3M28.4M130.5M78.4M90.1M94.6M
Good Will860.4M855.5M987.1M1.0B1.2B1.2B
Net Tangible Assets378.8M623.7M552.4M701.5M806.7M847.1M
Capital Surpluse1.1B1.5B1.6B1.5B1.8B1.9B

Repligen Key Income Statement Accounts

202120222023202420252026 (projected)
Interest Expense12.7M3.0M10.0M22.6M20.3M21.3M
Total Revenue670.5M801.5M638.8M634.4M729.6M766.0M
Gross Profit391.3M455.7M284.2M274.6M315.8M532.0M
Operating Income167.2M224.7M54.6M(35.1M)(40.4M)(38.4M)
Ebit164.8M220.3M56.2M(6.3M)(7.2M)(7.6M)
Ebitda203.3M277.3M124.3M80.3M92.3M96.9M
Cost Of Revenue279.3M345.8M354.5M359.8M413.8M234.1M
Income Before Tax153.5M219.1M64.1M(27.0M)(31.1M)(32.6M)
Net Income128.3M186.0M41.6M(25.5M)(23.0M)(24.1M)
Income Tax Expense25.3M33.2M22.6M(1.5M)(1.7M)(1.7M)
Research Development34.3M43.9M42.7M43.2M49.7M47.2M
Tax Provision25.3M33.2M10.1M(1.5M)(1.7M)(1.7M)
Net Interest Income(12.7M)(3.0M)(2.9M)(22.6M)(20.3M)(19.3M)

Repligen Key Cash Accounts

202120222023202420252026 (projected)
Change To Inventory(89.8M)(57.2M)41.0M56.9M51.2M53.8M
Change In Cash(113.5M)(80.4M)227.9M6.0M6.9M6.6M
Free Cash Flow47.7M38.7M74.9M142.5M163.9M172.1M
Depreciation38.4M57.0M68.1M86.6M99.5M104.5M
Other Non Cash Items20.4M(27.0M)(15.0M)5.4M6.2M6.5M
Capital Expenditures71.3M133.3M39.0M32.9M37.8M30.5M
Net Income128.3M186.0M41.6M(25.5M)(29.3M)(30.8M)
End Period Cash Flow603.8M523.5M751.3M757.4M871.0M914.5M
Investments(221.2M)(100M)(74.7M)(86.4M)(77.7M)(81.6M)
Change Receivables(7.8M)(20.9M)(46.5M)(3.6M)(3.2M)(3.4M)
Change To Netincome18.5M13.3M34.9M25.9M29.7M31.2M

Repligen Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Repligen's current stock value. Our valuation model uses many indicators to compare Repligen value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Repligen competition to find correlations between indicators driving Repligen's intrinsic value. More Info.
Repligen is rated fourth in return on equity category among its peers. It is rated fifth in return on asset category among its peers reporting about  14.44  of Return On Asset per Return On Equity. At this time, Repligen's Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Repligen's earnings, one of the primary drivers of an investment's value.

Repligen's Earnings Breakdown by Geography

Most indicators from Repligen's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Repligen current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Repligen. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing.
To learn how to invest in Repligen Stock, please use our How to Invest in Repligen guide.At this time, Repligen's Selling General Administrative is very stable compared to the past year. As of the 29th of January 2026, Enterprise Value Over EBITDA is likely to grow to 120.07, though Tax Provision is likely to grow to (1.7 M).
 2023 2024 2025 2026 (projected)
Gross Profit284.2M274.6M315.8M532.0M
Total Revenue638.8M634.4M729.6M766.0M

Repligen fundamental ratios Correlations

0.960.970.670.990.97-0.270.950.970.98-0.120.980.980.860.880.920.980.970.980.950.990.940.070.980.640.8
0.960.930.470.930.97-0.060.960.920.96-0.080.920.960.830.970.840.970.90.980.980.940.89-0.150.940.650.7
0.970.930.680.960.97-0.20.950.930.98-0.060.940.990.870.870.910.950.950.970.960.960.970.10.960.550.77
0.670.470.680.730.6-0.570.590.650.66-0.130.680.670.670.270.810.60.740.580.540.710.70.740.690.190.72
0.990.930.960.730.95-0.330.940.970.98-0.170.980.980.880.840.930.980.980.960.930.990.930.120.980.570.82
0.970.970.970.60.95-0.040.990.90.97-0.070.910.980.820.910.930.960.920.981.00.940.930.00.950.610.72
-0.27-0.06-0.2-0.57-0.33-0.04-0.02-0.42-0.220.12-0.41-0.19-0.390.07-0.21-0.24-0.41-0.140.01-0.35-0.24-0.49-0.30.01-0.5
0.950.960.950.590.940.99-0.020.890.96-0.020.90.970.770.910.920.940.90.970.990.930.89-0.020.940.580.71
0.970.920.930.650.970.9-0.420.890.96-0.071.00.950.890.860.850.970.980.950.880.990.90.040.970.550.84
0.980.960.980.660.980.97-0.220.960.960.00.970.990.890.90.930.980.980.990.960.980.950.051.00.510.81
-0.12-0.08-0.06-0.13-0.17-0.070.12-0.02-0.070.0-0.08-0.06-0.10.01-0.04-0.12-0.02-0.04-0.07-0.07-0.09-0.050.02-0.460.04
0.980.920.940.680.980.91-0.410.91.00.97-0.080.950.90.850.880.970.990.960.890.990.90.080.980.550.84
0.980.960.990.670.980.98-0.190.970.950.99-0.060.950.880.890.930.980.970.990.970.980.960.080.980.550.78
0.860.830.870.670.880.82-0.390.770.890.89-0.10.90.880.740.830.860.920.860.80.90.870.220.90.330.82
0.880.970.870.270.840.910.070.910.860.90.010.850.890.740.730.920.820.940.930.850.81-0.360.870.610.61
0.920.840.910.810.930.93-0.210.920.850.93-0.040.880.930.830.730.890.910.90.890.920.890.330.920.470.8
0.980.970.950.60.980.96-0.240.940.970.98-0.120.970.980.860.920.890.960.990.950.980.93-0.020.970.620.78
0.970.90.950.740.980.92-0.410.90.980.98-0.020.990.970.920.820.910.960.950.890.990.930.160.990.460.87
0.980.980.970.580.960.98-0.140.970.950.99-0.040.960.990.860.940.90.990.950.980.970.93-0.050.980.580.77
0.950.980.960.540.931.00.010.990.880.96-0.070.890.970.80.930.890.950.890.980.920.92-0.060.930.620.68
0.990.940.960.710.990.94-0.350.930.990.98-0.070.990.980.90.850.920.980.990.970.920.930.120.990.550.84
0.940.890.970.70.930.93-0.240.890.90.95-0.090.90.960.870.810.890.930.930.930.920.930.150.940.490.75
0.07-0.150.10.740.120.0-0.49-0.020.040.05-0.050.080.080.22-0.360.33-0.020.16-0.05-0.060.120.150.09-0.190.26
0.980.940.960.690.980.95-0.30.940.971.00.020.980.980.90.870.920.970.990.980.930.990.940.090.470.85
0.640.650.550.190.570.610.010.580.550.51-0.460.550.550.330.610.470.620.460.580.620.550.49-0.190.470.25
0.80.70.770.720.820.72-0.50.710.840.810.040.840.780.820.610.80.780.870.770.680.840.750.260.850.25
Click cells to compare fundamentals

Repligen Account Relationship Matchups

Repligen fundamental ratios Accounts

202120222023202420252026 (projected)
Total Assets2.4B2.5B2.8B2.8B3.3B3.4B
Other Current Liab55.8M63.3M46.4M66.3M76.3M80.1M
Net Debt(237.8M)(100.5M)(39.5M)(71.1M)(64.0M)(67.2M)
Retained Earnings194.1M397.3M438.8M407.4M468.5M491.9M
Cash603.8M523.5M751.3M757.4M871.0M914.5M
Net Receivables117.4M116.2M124.2M134.1M154.2M161.9M
Inventory184.5M238.3M202.3M143.0M164.4M172.6M
Other Current Assets25.9M19.8M33.2M31.6M36.3M38.2M
Total Liab608.3M620.9M853.2M856.9M985.5M1.0B
Total Current Assets931.7M998.1M1.1B1.1B1.2B1.3B
Accounts Payable36.2M27.6M19.6M32.1M37.0M38.8M
Short Term Debt263.6M291.6M75.1M15.1M17.4M16.5M
Intangible Assets337.3M360.6M400.5M397.9M457.6M480.5M
Other Assets28.2M2.5M1.7M282.1M253.9M266.6M
Common Stock553K556K558K561K645.2K408.0K
Other Liab32.3M28.4M130.5M78.4M90.1M94.6M
Good Will860.4M855.5M987.1M1.0B1.2B1.2B
Net Tangible Assets378.8M623.7M552.4M701.5M806.7M847.1M
Capital Surpluse1.1B1.5B1.6B1.5B1.8B1.9B
Today, most investors in Repligen Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Repligen's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Repligen growth as a starting point in their analysis.

Price Earnings To Growth Ratio

1.05

At this time, Repligen's Price Earnings To Growth Ratio is very stable compared to the past year.

Repligen January 29, 2026 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Repligen help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Repligen. We use our internally-developed statistical techniques to arrive at the intrinsic value of Repligen based on widely used predictive technical indicators. In general, we focus on analyzing Repligen Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Repligen's daily price indicators and compare them against related drivers.
When determining whether Repligen offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Repligen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Repligen Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Repligen Stock:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Repligen. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing.
To learn how to invest in Repligen Stock, please use our How to Invest in Repligen guide.
You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Will Life Sciences Tools & Services sector continue expanding? Could Repligen diversify its offerings? Factors like these will boost the valuation of Repligen. Anticipated expansion of Repligen directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Repligen data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth
1.6
Earnings Share
0.02
Revenue Per Share
12.602
Quarterly Revenue Growth
0.219
Return On Assets
0.013
Investors evaluate Repligen using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Repligen's intrinsic value—the estimated true worth—helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Repligen's market price to deviate significantly from intrinsic value.
It's important to distinguish between Repligen's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Repligen should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Repligen's market price signifies the transaction level at which participants voluntarily complete trades.